Consecutive approvals of Opdivo for Hodgkin's lymphoma to boost sales growth [Yahoo! Finance]
Pfizer, Inc. (PFE)
Last pfizer, inc. earnings: 4/28 06:45 am
Check Earnings Report
US:NYSE Investor Relations:
investors.pfizer.com/investors-overview/default.aspx
Company Research
Source: Yahoo! Finance
with adriamycin, vinblastine, and dacarbazine (AVD) chemotherapy, as a first-line treatment for stage III–IV chemotherapy in patients aged 12 years and older with Hodgkin lymphoma (HL). This landmark approval makes Opdivo the first anti-PD-1 immunotherapy to be officially approved for the first-line treatment of HL in the US. In the same week, Opdivo was also approved by the EMA for use in combination with Pfizer's antibody-drug conjugate Adcetris (brentuximab vedotin) in relapsed and refractory HL patients aged 5–30 years. These landmark approvals offer clinicians valuable additional options for treating patients as current treatments may be inaccessible or ineffective. These approvals have followed the completion of two key clinical trials. The Phase III SWOG 1826 trial has been completed in the US, and in Europe, the Phase II CheckMate-744 trial was completed at the end of 2024. The SWOG 1826 trial compared Adcetris in combination with AVD against Opdivo plus AVD, and assessed th
Show less
Read more
Impact Snapshot
Event Time:
PFE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PFE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PFE alerts
High impacting Pfizer, Inc. news events
Weekly update
A roundup of the hottest topics
PFE
News
- Jim Cramer on Pfizer: “I Just Need to Know Their Product Flow Better” [Yahoo! Finance]Yahoo! Finance
- ????????????? - ??????????????????2026-2035? [CNET News]CNET News
- Guggenheim Sees Favorable Risk-Reward for Pfizer (PFE) Ahead of Phase 3 Data [Yahoo! Finance]Yahoo! Finance
- Income Investors Face a Hard Truth About Pfizer's Payout Safety [Yahoo! Finance]Yahoo! Finance
- Is Pfizer Stock a Buy After This Win? [Yahoo! Finance]Yahoo! Finance
PFE
Earnings
- 2/3/26 - Beat
PFE
Sec Filings
- 3/27/26 - Form SCHEDULE
- 3/16/26 - Form 4
- 3/12/26 - Form ARS
- PFE's page on the SEC website